Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Jan;43(1):152-161.
doi: 10.1002/jpen.1172. Epub 2018 Apr 21.

Influence of Human Milk and Parenteral Lipid Emulsions on Serum Fatty Acid Profiles in Extremely Preterm Infants

Anders K Nilsson  1 , Chatarina Löfqvist  1 , Svetlana Najm  2 , Gunnel Hellgren  1   3 , Karin Sävman  2 , Mats X Andersson  4 , Lois E H Smith  5 , Ann Hellström  1
Affiliations
Randomized Controlled Trial

Influence of Human Milk and Parenteral Lipid Emulsions on Serum Fatty Acid Profiles in Extremely Preterm Infants

Anders K Nilsson et al. JPEN J Parenter Enteral Nutr. 2019 Jan.

Abstract

Background: Infants born prematurely are at risk of a deficiency in ω-6 and ω-3 long-chain polyunsaturated fatty acids (LC-PUFAs) arachidonic acid (AA) and docosahexaenoic acid (DHA). We investigated how fatty acids from breast milk and parenteral lipid emulsions shape serum LC-PUFA profiles in extremely preterm infants during early perinatal life.

Methods: Ninety infants born < 28 weeks gestational age were randomized to receive parenteral lipids with or without the ω-3 LC-PUFAs eicosapentaenoic acid (EPA) and DHA (SMOFlipid: Fresenius Kabi, Uppsala, Sweden, or Clinoleic: Baxter Medical AB, Kista, Sweden, respectively). The fatty acid composition of infant serum phospholipids was determined from birth to postmenstrual age 40 weeks, and in mother's milk total lipids on postnatal day 7. Enteral and parenteral intake of LC-PUFAs was correlated with levels in infant serum.

Results: Infants administered parenteral ω-3 LC-PUFAs received 4.4 and 19.3 times more DHA and EPA, respectively, over the first 2 weeks of life. Parenteral EPA but not DHA correlated with levels in infant serum. We found linear relationships between dietary EPA and DHA and infant serum levels in the Clinoleic (Baxter Medical AB) group. The volume of administered SMOFlipid (Fresenius Kabi) was inversely correlated with serum AA, whereas Clinoleic (Baxter Medical AB) inversely correlated with serum EPA and DHA.

Conclusions: There appears to be no or low correlation between the amount of DHA administered parenterally and levels measured in serum. Whether this observation reflects serum phospholipid fraction only or truly represents the amount of accreted DHA needs to be investigated. None of the parenteral lipid emulsions satisfactorily maintained high levels of both ω-6 and ω-3 LC-PUFAs in infant serum.

Keywords: arachidonic acid; docosahexaenoic acid (DHA); extremely preterm; human milk; long-chain polyunsaturated fatty acids (LC-PUFA); parenteral nutrition.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient enrollment flowchart.
Figure 2
Figure 2
(A) Histogram showing the number of days infants received parenteral lipid nutrition. (B) Total number of infants receiving full enteral feeding (> 150 mL kg−1 d−1).
Figure 3
Figure 3
Relationship between total intake of DHA and infant serum level on postnatal day 14. (A) Total DHA administered enterally (mother's milk and donor milk) vs infant serum in the Clinoleic (Baxter Medical AB, Kista, Sweden) group and (B) SMOFlipid (Fresenius Kabi, Uppsala, Sweden) group. (C) Total DHA administered parenterally vs infant serum levels in the SMOFlipid group (Fresenius Kabi). (D) Total DHA administered enterally and parenterally vs infant serum levels in the Clinoleic (Baxter Medical AB) and SMOFlipid (Baxter Medical AB) groups. DHA, docosahexaenoic acid.
Figure 4
Figure 4
Relationship between total intake of EPA and infant serum levels on postnatal day 14. (A) Total EPA administered enterally (mother's milk and donor milk) vs infant serum levels in the Clinoleic (Baxter Medical AB, Kista, Sweden) group (B) and in the SMOFlipid (Fresenius Kabi, Uppsala, Sweden) group. (C) Total EPA administered parenterally vs serum levels in the SMOFlipid (Fresenius Kabi) group. (D) Total volume of administered parenteral lipid emulsion vs infant serum EPA levels in the Clinoleic (Baxter Medical AB) group. EPA, eicosapentaenoic acid.
Figure 5
Figure 5
Relationship between total intake of parenteral lipid emulsion and infant serum AA levels on postnatal day 14. Total volume of administered parenteral lipid emulsion vs infant serum AA levels in the SMOFlipid (Fresenius Kabi, Uppsala, Sweden) group. AA, arachidonic acid.
See this image and copyright information in PMC

References

    1. Driscoll DF, Bistrian BR, Demmelmair H, Koletzko B. Pharmaceutical and clinical aspects of parenteral lipid emulsions in neonatology. Clin Nutr 2008;27:497‐503. - PubMed
    1. Qawasmi A, Landeros‐Weisenberger A, Bloch MH. Meta‐analysis of LCPUFA supplementation of infant formula and visual acuity. Pediatrics 2013;131:e262‐e272. - PMC - PubMed
    1. Fang PC, Kuo HK, Huang CB, Ko TY, Chen CC, Chung MY. The effect of supplementation of docosahexaenoic acid and arachidonic acid on visual acuity and neurodevelopment in larger preterm infants. Chang Gung Med J 2005;28:708‐715. - PubMed
    1. Wang Q, Cui Q, Yan C. The effect of supplementation of long‐chain polyunsaturated fatty acids during lactation on neurodevelopmental outcomes of preterm infant from infancy to school age: a systematic review and meta‐analysis. Pediatr Neurol 2016;59:54‐61.e1. - PubMed
    1. Lapillonne A. Enteral and parenteral lipid requirements of preterm infants. World Rev Nutr Diet 2014;110:82‐98. - PubMed

Publication types

MeSH terms